CAR-T Cell Therapy for Autoimmune Disease
Part of Bones, joints & muscles, Brain & nervous system, Eyes & vision, Heart & circulation, Immune system & allergy, Mouth & dental, Skin clinical trials.
This early-stage trial tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune diseases like lupus, scleroderma, vasculitis, muscle inflammation, and Sjögren's syndrome that haven't responded well to standard treatments. The therapy works by modifying your own immune cells to target and reduce the B cells driving your disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–70 years old with adequate organ function (healthy liver, kidneys, heart, and blood counts)
- Diagnosed with one of five autoimmune diseases: lupus (SLE), scleroderma (SSc), vasculitis (AAV), inflammatory muscle disease (IIM), or Sjögren's syndrome (pSS)
- Active disease despite at least 2 months of stable treatment with current medications
- No recent or active infections (HIV, hepatitis, TB, or certain viral infections)
- Willing to use effective birth control for 12 months after receiving the cell infusion
- Not pregnant or breastfeeding, and no prior CAR-T or gene-modified cell therapy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called RD06-05, which uses specially engineered immune cells to target and potentially reset parts of the immune system that are attacking your own body. It is being studied for several autoimmune conditions like lupus, vasculitis, kidney diseases, and more.
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
This study tests an immune-cell treatment (CAR-T, called BRL-301) in people with certain autoimmune diseases that are active and hard to control. It may help your immune system calm down if standard treatments have not worked or your disease has returned.
This trial tests a new CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells. It's designed for people with certain autoimmune diseases like lupus, scleroderma, vasculitis, myositis, or Sjögren's syndrome that are not controlled by standard treatments.
This trial tests if a special immune cell therapy (CAR-T) can help people with certain autoimmune diseases like lupus, Sjogren's syndrome, scleroderma, myositis, vasculitis, or antiphospholipid syndrome that haven't improved with standard treatments. It is a very early phase study to check safety and effectiveness.
This study tests a new treatment called CAR T-cell therapy for people with severe autoimmune diseases that haven't gotten better with standard treatments. The goal is to see if it can help control the disease by reprogramming your immune cells.
Hear when a new Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.